Publications by authors named "Raafat M Abdelfattah"
This study aimed to investigate the frequency of MYC/BCL2 co-expression using immunohistochemistry (IHC) in Egyptian patients with diffuse large B-cell lymphoma (DLBCL) and its impact on treatment outcomes, overall survival (OS), and disease-free survival (DFS). A total of 100 adult patients with newly diagnosed DLBCL were included in the study and treated with the R-CHOP regimen. The cases were classified into germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB) subtypes based on IHC.
View Article and Find Full Text PDFArticle Synopsis
- - The study compared the effectiveness of post-transplant cyclophosphamide (PTCy) with methotrexate (MTX) and cyclosporine-A (CsA) in preventing graft-versus-host disease (GVHD) in patients receiving peripheral blood stem cell transplants from matched related donors.
- - Among the 75 patients in each group, those receiving PTCy/CSA experienced significantly lower rates of chronic GVHD (13.4%) compared to those on MTX/CsA (38.6%).
- - Overall survival and disease-free survival rates were similar for both groups after two years, indicating that while PTCy may offer benefits in reducing chronic GVHD, it does not significantly improve survival
JAK2, CALR, MPL and triple-negative mutational status has a direct impact on symptom severity and disease burden assessed by MPN10 score in myeloproliferative neoplasms (MPNs). Among 93 patients; median MPN10 score was 48 (5-76) in JAK2 mutants versus 25 (4-80) in JAK2 negative (p < .001); 22.
View Article and Find Full Text PDFAllogeneic hematopoietic stem cell transplantation (allo-HSCT) from a geno-identical matched sibling (MSD) is one of the most successful therapies in patients with non-malignant hematological disorders. This study included 273 patients with severe aplastic anemia (SAA), 152 patients with B-Thalassemia major (BTM), 31 patients with Fanconi's anemia (FA), 20 patients with congenital immunodeficiency diseases (ID), and 13 patients with inherited metabolic disorders (IMD) allografted from a MSD. In SAA, the 8-year overall survival (OS) of the whole group patients was 74%.
View Article and Find Full Text PDF